Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 138 (9) , 1973-1981
Abstract
No abstract availableKeywords
Funding Information
- Janssen Scientific Affairs
This publication has 26 references indexed in Scilit:
- Sebaceous Gland Atrophy in Psoriasis: An Explanation for Psoriatic Alopecia?Journal of Investigative Dermatology, 2016
- Skin Microbiome Surveys Are Strongly Influenced by Experimental DesignJournal of Investigative Dermatology, 2016
- Bioaccessibility of pesticides and polychlorinated biphenyls from house dust: in-vitro methods and human exposure assessmentJournal of Exposure Science & Environmental Epidemiology, 2012
- Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skinArchives of Dermatological Research, 2011
- Innate immunity in the pathogenesis of psoriasisArchives of Dermatological Research, 2011
- UniFrac: an effective distance metric for microbial community comparisonThe ISME Journal, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- The Role of Streptococcal Infection in the Initiation of Guttate PsoriasisArchives of Dermatology, 1992
- Studies on Sweat Retention in Various DermatosesArchives of Dermatology, 1955